Aurodox is an elfamycin-like natural product from the soil bacterium Streptomyces goldiniensis, that can block translation through inhibition of elongation factor but has also recently been shown to inhibit Type III Secretion Systems. To gain a better understanding of its mechanism of action and to assess the utility of this compound as an anti-virulence molecule we have been using a multidisciplinary approach to understand the mode of action and biosynthesis of aurodox. Investigating the mode of action of aurodox in Shiga Toxin-producing Escherichia coli (STEC) we have shown that it downregulates expression of T3SS, inhibits epithelial colonisation and does not activate the SOS response that results in Shiga toxin production. We have also shown that aurodox protects mice from Shiga-toxin mediated renal injury and colonic hyperplasia. In parallel we have identified and cloned the biosynthetic gene cluster responsible for the biosynthesis of aurodox by Streptomyces goldiniensis, predicting, characterising and dissecting its biosynthetic pathway, opening routes to engineering novel aurodox derivatives. Our data suggest that aurodox may represent a useful candidate therapeutic for the treatment of STEC infections.